



BioPharmica Limited

Bridging Biotechnology Borders

BioPharmica (ASX: BPH) ASX Announcement

13 November 2009

Companies Announcements Office
Australian Securities Exchange Limited
10th Floor, 20 Bond Street
Sydney NSW 2000

NHMRC \$608,500 Grant for HLS5

BioPharmica Limited (BPH) is pleased to announce that Professor Peter Klinken and his team at the Western Australian Institute for Medical Research have been awarded a National Health and Medical Research Council (NHMRC) Grant titled: "Characterization of haemopoietic lineage determining genes". Research Support grants such as the NHMRC aim to provide funding to support the research undertaken to promote the health of Australians. The grant will be conducted over 3 years. The NHMRC is Australia's peak body for supporting health and medical research; and is the leading health research agency for the country.

Haemopoiesis is the process by which blood cells develop from stem cells. This process is tightly regulated and is dependant upon the appropriate expression of genes at each developmental stage within various lineages. The work focuses on two genes (Mlf1 and Hls5) that are involved in determining lineage commitment and affect the expression of key hemopoietic regulators. If these genes are aberrantly expressed, leukemias and other blood disorders can develop.

The tumour suppressor gene HLS5 will be part of the Molecular Discovery Systems IPO on the Australian Securities Exchange. Molecular Discovery Systems will be a company dedicated to HLS5, the Anti-Mitotic Drug Discovery Development Program along with its current high content screening facility. Under a planned 'spin off' process, BioPharmica (ASX: BPH) shareholders will receive a share at no cost in Molecular Discovery Systems for every listed BioPharmica share that they hold five days after the date that shareholder approval of the spin off is obtained, and this is expected to take place in mid December 2009.

For more information contact:

Mr David Breeze
BioPharmica Limited
Tel : +61 9 9328 8366

Yours sincerely,

David Breeze
Chairman